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Abstract
Introduction: Tight glucose control in the ICU has been proven difficult with an increased risk for hypoglycaemic
episodes. Also the variability of glucose may have an impact on morbidity. An accurate and feasible on-line/
continuous measurement is therefore desired. In this study a central vein catheter with a microdialysis membrane
in combination with an on-line analyzer for continuous monitoring of circulating glucose and lactate by the central
route was tested.
Methods: A total of 10 patients scheduled for major upper abdominal surgery were included in this observational
prospective study at a university hospital. The patients received an extra central venous catheter with a
microdialysis membrane placed in the right jugular vein. Continuous microdialysis measurement proceeded for 20
hours and on-line values were recorded every minute. Reference arterial plasma glucose and blood lactate samples
were collected every hour.
Results: Mean microdialysis-glucose during measurements was 9.8 ± 2.4mmol/l.No statistical difference in the
readings was seen using a single calibration compared to eighth hour calibration (P =0.09; t-test). There was a
close agreement between the continuous reading and the reference plasma glucose values with an absolute
difference of 0.6+0.8mmol, or 6.8+9.3% and measurements showed high correlation to plasma readings (r = 0.92).
Thelimit of agreement was 23.0%(1.94 mmol/l) compared to arterial plasma values with a line of equality close to
zero.However, in a Clarke-Error Grid 93.3% of the values are in the A-area,and the remaining part in the B-area.
Mean microdialysis-lactate was 1.3 ± 1.1mmol/l. The measurements showed high correlation to the blood readings
(r = 0.93).
Conclusion: Continuous on-line microdialysis glucose measurement in a central vein is a potential useful
technique for continuous glucose monitoring in critically ill patients, but more improvements and testingare
needed.
Keywords: Continuous glucose monitoring, intravenous microdialysis, intensive care, hyperglycaemia, hypoglycae-
mia, lactate
Introduction
A positive effect of a tight glucose control in critically ill
patients treated in the ICU was postulated a decade ago.
The initial study in 2001 demonstrated a remarkable
effect on both mortality and morbidity in ICU patients
[1]. Later diverging results have been published, andin a
large multi-centre trial, Normoglycemia in Intensive
Care Evaluation-Survival Using Glucose Algorithm
Regulation(NICE-SUGAR), the treatment group had an
even higher mortality than the control group [2].
A concern for an increased risk for hypoglycaemia with
the intensive insulin treatment has emerged. Up to 18% of
the patients subjected to intensive insulin treatment have
had episodes of hypoglycaemia [3]. Whether these hypo-
glycaemic periods have an impact on the worsened out-
come is debated. To reduce the risk for hypoglycaemia,
different ICUs use different protocols for monitoring glu-
cose levels with some recommending sampling every two
hours, which is time, cost and staff consuming[4]. Today
the standard routine for glucose measurement in ICU is
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repeated blood gas analyses. Bedside measurement devices
have been demonstrated to differ more than 20% from the
laboratory reference value [5]. In addition, recent studies
point to a correlation between the variability of glucose
and mortality [6-8].
Due to this, the need for a reliable on-line real time
measurement of glucose has emerged. Continuous glucose
monitoring (CGM) can be potentially instrumental in pre-
venting hypoglycaemia and a high glucose variability [9].
Several different techniques have been developed during
recent years, either using interstitial or intravascular posi-
tioning for measurements[10]. The use of microdialysis as
a tool for measuring glucose in the ICU over longer peri-
ods of time has been suggested. The subcutaneous devices
have been tested in both adults and children admitted in
the ICU and results are diverging[11-14].In critical ill
patients tissue perfusion can be altered and, therefore, sub-
cutaneous glucose measurement may be affected and may
not represent circulating glucose levels accurately[11].
Intravenous microdialysis has previously been studied
and proven useful [15]. However, in critically ill patients
the peripheral route is not always accessible and a central
vein solution might be preferred[16].In addition, a central
vein allows for a catheter with a larger membrane sur-
face, which has been shown to improve the agreement to
plasma readings.The purpose of this study was to test a
central venous catheter with a microdialysis membrane
in combination withan on-line analyser and monitor as a
principle for CGM. Continuous online measurements
were performed onpatients scheduled for major upper
abdominal surgery during surgery and postoperative care
for 20 hours. For this study a prototype of a commercial
product was used.
Material and methods
Patients (n = 10) scheduled for major upper abdominal
surgery between October 2009 and December 2010 at
Karolinska University Hospital, Huddinge, were enrolled in
this prospective study. Inclusion criteria were patients
scheduled for surgery involving a central venous access as
clinical routine. Exclusion criteria were: 1). Any coagula-
tion abnormality; 2). Planned placement of central vein
catheter anywhere else but in the right internal jugular
vein; 3). A central vein catheterposition deviating from
protocol; 4). No informed consent; 5). Patient under
18 years of age. The study design was reviewed and
approved by the regional ethics committee, EPN, in Stock-
holm. The subjects were informed about the purpose and
the nature of the study and the risks involved before giving
written informed consent. This study was observational
and,consequently,no change in the perioperative care of
the patient was made except for the insertion of an extra
central vein catheter with the microdialysis membrane.
The patients were studied during surgery and at the
postoperative ward for a total of 20 hours. None of the
patients needed the ICU ward during the study.
Before surgery, the patients received a standard two-
lumen central venous catheter and, in addition, a second
one-lumen central venous catheter with a microdialysis
membrane.Both were placed in the right jugular vein. As a
clinical routine, an intravenous glucose infusion was given
(25 mg/kg/h; 5% solution) during the whole study period
through the distal lumen of the standard central venous
catheter. The tip of the central venous catheter with the
microdialysis membrane was placed proximal to the glu-
cose infusion lumen to minimize a high false glucose
value. A distance more than 3.5 cm between the tips was
the target. The catheter placement was documented post-
operatively by chest X-ray. The microdialysis catheter had
a dialysis membrane length of 40 mm and a diameter of 4
Fr (Eirus SLC, Dipylon Medical AB, Solna, Sweden). The
standard central venous catheter was either a two-lumen
catheter with a length of 15cm and a diameter of 5 Fr (BD
Careflow™, Becton Dickinson Medical Surgical Systems,
Franklin Lakes, NJ, USA), or a three-lumen catheter with
a length of 16 cm and a diameter of 12 F (Mahurkar™,
Covidien, Mansfield, MA, USA). Patients routinely
received insulin when glucose levels were higher than
11mM.
Microdialysis was started immediately after insertion
of the catheter but registration started after a run-in
time of not less than 30 minutes. Continuous microdia-
lysis measurement then proceeded for 20 hours and on-
line values of glucose and lactate were recorded every
minute (Eirus, Dipylon Medical AB, Solna, Sweden).
The on-line device analyses glucose and lactate every
second and the screen present a minute average updated
every second. The microdialysis catheter was perfused
with saline by a pump located in the Eirus monitor
(Figure 1). The microdialysate was analysed for glucose
and lactate in an on-line analyser module utilising glucose
oxidase (GOD) and lactate oxidase (LOD) followed by
an electrochemical detection of H2O2. Results from the
analyser are sent to and displayed on the Eirus monitor
(Figure 1). Two separate reference arterial plasma samples
were collected every hour, two minutes apart;blood sam-
ples were kept on ice and plasma was obtained by centri-
fugation (1,200xg for 10 minutes at 4oC) within 90
minutes andstored at -20oC until later analysed. At the
same time points, two reference blood lactate samples
were collected.These were immediately placed on ice and
part of the sample was immediately mixed with 14% per-
chloric acid to a final concentration of 4.7 mM perchloric
and stored at -20oC for later analyses. Plasma glucose and
whole blood lactate were analyzed as described before[17].
Plasma glucose was analysed on an automatic analyser
(Konelab 20, Thermo Scientific, Jönköping, Sweden) using
a GOD-POD analysis (Thermo Fisher Scientific, Vantaa,
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Finland). Whole blood lactate was analysed using a 96-well
photo spectrometer and a method based on lactate dehydro-
genase (DiaSys Diagnostic Systems, Holzheim, Germany).
Retrospectively, the microdialysis measurements were
calibrated to plasma glucose and blood lactate values.
Two different ways of calibration were used: using the
first plasma value only (MD1) or recalibration to plasma
glucose every eighth hour (MD8). A mean plasma value
of lactate and glucose, derived from the samples col-
lected two minutes apart, was calculated and compared
to the microdialysis measurements. The plasma value
was compared to the microdialysis value.The transport
of the dialysate from the microdialysis catheter to the
on-line analysis takes 10 minutes and, therefore, the
microdialysis values were corrected for 10 minutes.
Comparisons of the microdialysis and the hourly
plasma/blood samples were done using different methods
including regression analyses, Bland-Altman plots and
Clarkeerror grids. Since this is the first time a central
venous catheter with a microdialysis membrane in com-
bination with an on-line sensor was tested, we designed
the study as a pilot study and did not perform any power
calculations. Student’s t-test was used for statistical com-
parison of data.
Results
Continuous microdialysis proceeded for 20 hours in all
patients included in the study. The patients had major
upper abdominal surgery; pancreas resection (n = 3), liver
resection (n = 6) or gastric resection (n = 1). Ten patients
were studied per protocol, eight females and two men,
mean age 59.7 yrs (range 27 to 81). Six patients received a
BD Careflow™ and four a Mahurkar™ central vein cathe-
ter. All patients, at some point during the study, received
noradrenalin and five of the patients received insulin. No
adverse events were observed that were associated with
the central vein catheter or with the microdialysis mem-
brane. The mean distance between the tips of the two
catheters was 59mm (range 39 to 82 mm), with the micro-
dialysis catheter as the most proximal. X-ray images were
used for documentation of the individual placement.
The time plots of comparisons between all the micro-
dialysis recordings and the hourly blood measurements
of all the individual patients can be found in the Addi-
tional files. Online microdialysis measurements were pre-
sented every minute but only the results from the same
time as the hourly blood samples are used for further
comparison. A total of 195 individual values were col-
lected and analyzed. The recorded glucose values ranged
from 4.2 to 17.1 mmol/l.
Mean microdialysis-glucose using a single calibration
(MD1) was 9.6 ± 2.5mmol/l (SD) and eight-hour calibra-
tion (MD8) 9.8 ± 2.4 mmol/l (SD). Both calibration meth-
ods showed close agreement between the continuous
reading and the reference plasma glucose valuesin 8 of the
10 patients(see Additional file 1). MD1 calibration showed
a mean absolute glucose difference of 0.85 ± 0.82 mmol/l
(SD) or 8.8 ± 8.4% (SD) and MD8 calibration 0.61 ± 0.76
mmol/l (SD), or 6.8 ± 9.3% to the reference plasma value.
Both calibration methods showed high correlations to
the plasma readings, MD1 r= 0.89 (P <0.001) and MD8
r = 0.92 (P <0.001; t-test). The agreement between
Đ
Figure 1 Schematic design. A. Schematic design of the microdialysis (MD) system: 1. MD system with sensor holder and display, 2. Perfusate
line (sodium chloride), 3. Dialysate line, 4. MD sensor with integrated vials, 5. MD catheter, 6. Adjacent 2 lumen central venous catheter.
B. Zoomed schematic design of the insertion area; 5. Proximally inserted MD catheter; 6. Distally inserted central venous catheter. C. Picture of
the central vein catheter with the microdialysis membrane (arrows).
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MD-glucose values and plasma glucose values is pre-
sented as a Bland-Altman plot (Figure 2). The lines of
equality were close to zero for both ways of calibrating.
The MD values showed a limit of agreement ( ± 1.96 SD:
CI 95%) of 24.2% (2.34mmol/l) using single calibration
(MD1) and 23.0% (1.94 mmol/l) using MD8 compared to
arterial plasma levels. The difference in the limit of agree-
ment between the two calibration methods is not statisti-
cally significantly different (P =0.09; t-test).Presented in a
Clarke error grid, 100% of all values are found in the A
or B areas. In MD1, 92.7% of the values are in the A-area
and 7.3% in the B-area, (Figure 3). In MD8, 93.3% of the
values are in the A-area and 6.7% in the B-area.
Lactate measurements of the microdialysis were cali-
brated in the same way as for glucose, retrospectively
using single and eight-hour calibration. Mean microdialy-
sis lactate using either calibration was 1.3 ± 1.1 mmol/l.
Although for the lactate the agreement of the microdialy-
sis with the reference value was not as good as for the glu-
cose, the changes over time were very well represented by
the microdialysis measurements (see Additional file 2).
MD1 calibration showed a mean absolute difference of
0.28 ± 0.35 mmol/l (SD) or 23.4 ± 21.8% (SD) and MD8
calibration 0.25 ± 0.35 mmol/l (SD) or 20.5 ± 22.3% (SD).
Both calibration methods showed good correlation to
the plasma readings, MD1 r= 0.94 (P <0,001) and MD8
r = 0.93(P <0,001)(Figure 4).The agreement between
MD-lactate and blood lactate values is also presented in a
Bland-Altman plot (Figure 5).The limits of agreement
(± 1.96 SD; CI 95%) were for MD1 60.8% or 0.88 mmol/l
and forMD860.3% or 0.86 mmol/l (Figure 5).
Discussion
In the present pilot study, wetested a central vein cathe-
ter with a microdialysis membrane in combination with
an on-line analyzer and monitor for continuous glucose
and lactatemonitoring. Eight of the 10 patients included
show good agreement. In the other two patients, the
trends in glucose fluctuations were the same, but the
absolute agreement was imperfect. Reasons for this are
discussed below. The limits of agreement in the Bland-
Altman were about 24%. Despite this, all of the values
measured with the microdialysis were in the non-dan-
gerous zones in the Clarke-error grid. The lactate corre-
lations were high, but the Bland-Altman plots showed
limits of agreement up to 60%.
Our results obtained during major surgery suggest that
the central vein monitoring using microdialysis is an
attractive approach for patients in need of a central
venous line. A central venous approach gave the possibi-
lity to use a large enough membrane area for a high flow
rate of microdialysis fluid, still with a high level of equili-
bration. This is impossiblein peripheral veins. Another
advantage of the microdialysis techniques is that no
blood sampling is needed since the analyses is derived
from the dialysate. Using blood sampling may affect the
risk for thrombosis and blood stream infections.
Two different calibrations were used, a single calibration
(MD1) to the first plasma value and one calibration every
eighth hour (MD8). No statistical difference in the results
was observed. No apparent drift was observed in any of
the patients with either calibration, indicating that a future
clinical devise possibly can have limited calibrations.
The results show a good correlation and a line of equal-
ity close to zero. However, the limits of agreement were
>20% with either the single or every eighth hour calibra-
tion protocol. According to the ISO certification criteria
for point of care glucometers,glucose values must be
within 20% of plasma reference more than 95% of the
time, when glucose values >4.1 mmol/l. Below 4.1 mmol/l
 
Figure 2 Bland-Altman plots. Mean reference plasma glucose vs. microdialysis glucose, eight-hour calibration (MD8; left) and single calibration
(MD1; right). Bold line: lines of equality; dotted lines: limits of agreement (1.96*SD).
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glucose values need to be within 0.8 mmol/l more than
95% of the time [18].Recently,a consensus meeting con-
cluded acceptable criteria for continuous glucose measure-
ment as 95% of readings must be within 12.5% and99%
within 20% of reference standard[19]. According to these
upcoming consensus criteria, 85% and 91% of our values
were within 12.5% and 20% of the reference standard,
respectively. Our results showed that measurements from
two patients dominate the outlying values, 69.2% (9/13). If
these two patients are excluded from analysis, we reach
95% and 98%, respectively, showing that our approach has
the potential to reach these criteria, but that testing in lar-
ger studies is needed.Most of the outlier values can be
explained by the limitations in our study. The first patient-
presented suboptimal recordings despite calibration(see
Additional file 1). However, this patient had large changes
in glucose levels that were shown by the microdialysis
methods but not to the same extent as in the plasma refer-
ence values. All these changes were the result of clinical
interferences, like changes in glucose infusion, corticoster-
oid and insulin treatment. The suboptimalagreement may
be explained by the differences in arterial (reference sam-
ple) and venous glucose (microdialysis measure) level,espe-
cially during rapid changes. The ninth patientdemonstrates
a possible calibration problem, which might be explained
by the fact that we used a prototype analyser. The lactate
Figure 3 Clarke-Error Grid. Reference glucose vs. microdialysis glucose, eight-hour calibration (MD8; left),and single calibration (MD1; right).
Figure 4 Regression analysis. Reference blood lactate vs. microdialysis lactate, eight-hour calibration (MD8; left),and single calibration (MD1; right).
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readings in the same patient showed closer agreement,
indicating a functional microdialysis membrane and lactate
analyser.The remaining outliers were single “off-line”
plasma values in four separate patients.
Despite these outliers, all measurements are found
within the A or B area in the Clarke-Error grid. Although
the Clarke-Error grid is developed for point-of-care glu-
cose analysers for diabetic patients [20], it may serve as a
risk estimator. Similar results were recently obtained in
conjunction with cardiac surgery using a similar intravas-
cular microdialysis catheter but the analyses were not
performed using the on-line measurements [21].
Our study has several limitations. One limitation in our
study is the hourly plasma reference sampling. More fre-
quent samples may have improved the accuracy. In addi-
tion, we only measured up to 20 hours and cannot
conclude the catheter’s performance beyond that point.
The study was designed as a pilot study and we included
only 10 patients. Larger studies are needed to verify our
finding and to study the usefulness of this approach in
the ICU.
Another limitation is that we used two separate cen-
tral vein catheters. To minimize the risk for false high
values of glucose at the microdialysis membrane due to
the glucose infusion, the mean distance between the two
catheter tips was 59 mm. However, postoperative mobi-
lization may have varied the distance between the two
catheter tips and at different measurement points this
might have varied the influence of the glucose infusion.
In the future, a device with an integrated microdialysis
membrane to a standard central venous catheter will be
available.
In the present study we compared central venous to
arterial reference measurements which may also contri-
bute to the disagreement observed. These figures should
be compared to plasma glucose analyses sampled at the
same time point in an artery and a peripheral vein in
stable healthy volunteers, giving a limit of agreement of
12% [16]. However, as mentioned above during fast
changes in glucose due to clinical interferences, these
two different sites might respond differently.
Finally, since we included surgical patients in this study
we only obtained glucose levels between 4.2 and 17.1
mmol/l and not in the hypoglycemic range. Due to this
we cannot conclude the usefulness of this approach in
the ICU until specifically studied.
Not only glucose measurements are of importance for
ICU patients. A high lactate level is often seen in criti-
cally ill, unstable patients and is often related to poorer
outcome [22]. Therefore, monitoring of lactate could
help ICU treatment, especially in unstable situations.An
absolute lactate value is of less value than the trend over
time in clinical practice.
Lactate analyses have proven sensitive to sample hand-
ling and calibration.Lactate concentration is significantly
higher in plasma than in erythrocytes[23,24]resulting in a
30 to 40% difference between plasma and whole blood
[25]. Measurements are, therefore, easily affected if the
sample is not immediately stored on ice to minimize the
additional lactate production in erythrocytes. In our stu-
dies, the lactate was measured in whole blood samples in
which all processes were immediately halted by precipi-
tating all the proteins and freezing the sample in liquid
nitrogen. Since we calibrated the microdialysis to the
whole blood measurements, the difference between whole
blood and microdialysate is eliminated. However, we can-
not exclude a difference in whole blood and microdialysis
lactate appearing over time. In addition, the microdialysis
readings were performed in venous blood, whereas the
plasma samples were arterial.
Figure 5 Bland-Altman plots. Mean reference blood lactate vs. microdialysis lactate, eight-hour calibration (MD8; left) and single calibration
(MD1; right). Bold line: lines of equality; dotted lines: limits of agreement (1.96*SD).
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Conclusions
This study has demonstrated that intravascular online
microdialysis technique can be a useful tool for continuous
glucose measurement. The central venous route is a feasi-
ble way of gaining reliable vascular access in ICU patients
and it offers the possibility to have a large microdialysis
membrane area, improving agreement to plasma values.
The use of the combined central vein catheter and on-line
analyzer is a potential approach for CGM in the ICU but
improvements and more testing, especially in an ICU
population, are needed. Further validating studies should
use central vein samples as references to eliminate con-
founders based on these limitations. Lactate values were
also analyzed, demonstrating a clear and accurate trend
over time but absolute values had a low agreement.
Key messages
- In this pilot study, glucose measurements by a central
venous catheter with a microdialysis membrane combined
with an online analyzer recording have been studied in
surgical patients over a period of 20 hours.
- The intravascular microdialysis technique shows pro-
mising results compared to reference plasma values, justi-
fying further testing.
- The technique may be a useful tool for continuous glu-
cose measurement in ICU-patients, but needs to be tested
in this population.
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Additional file 1: Diagrams of glucose measurement for each
subject. Diagrams of plasma glucose values vs. microdialysis values, MD8
and MD1 calibration.
Additional file 2: Diagrams of lactate measurement for each
subject. Diagrams of blood lactate values vs. microdialysis values, MD8
and MD1 calibration.
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